Abstract: The present invention is concerned with the zinc tranexamate represented by the formula: ##STR1## or its pharmacologically acceptable organic acid salts. The zinc compounds of the present invention, when given in smaller doses than tranexamic acid and cetraxate hydrochloride, exhibit anti-inflammatory and anti-ulcer activities, and are tasteless and odorless, thus being easy to be administered; in particular, the organic acid salts are water-soluble and can be processed into the liquid dosage forms of injectable solution and liquid preparations for external uses.

Abstract: The present invention relates to the use of Triclosan in the manufacture of a composition for the prevention, inhibition and/or reduction of aphthous ulcers. Preferably, the compositions are oral compostions such as toothpastes and mouthwashes. The oral composition is especially preferably in a gel form. Preferably the Triclosan is used together with a zinc salt such as zinc citrate, and or a polymer that enhances the delivery of the Triclosan.

Abstract: The invention relates to the use of complexes and chelates resp., of antitics with bivalent and/or trivalent metals in antiulcer drugs, to new complexes and chelates resp., of antibiotics with bivalent and/or trivalent metals and to processes for the obtaining thereof.

Abstract: A method of treating degenerative musculoskeletal diseases such as rheumatoid arthritis and osteoaarthritis in an animal, typically a human, comprises administering to the animal, typically enterally, in a convenient dosage form, a therapeutically effective amount of the beneficiated extracts of the plants ASHWAGANDHA (Withania somnifera), SALLAI GUGGUL (Boswellia serrata), TURMERIC (Curcuma longa), and GINGER (Zingiber officinale) in a predetermined proportion relative to each other with or without other biologically active inorganic ingredients, such as zinc sulphate. The beneficiated plant extracts are made in accordance with a novel process which is also disclosed.

Abstract: The present invention covers 2-aminoethanesulfonic acid zinc complex compound as represented by the formula [I]: ##STR1## as well as a process for producing the same, and an anti-hepatitis agent, liver function improving agent and anti-ulcer agent. As compared with 2-aminoethanesulfonic acid, glutathione and glycyrrhizin, the compound (I) of the present invention exhibits improved anti-hepatitis activity, and also strengthens detoxicating activity toward various compounds to thereby develop liver function improving activity, while the said compound shows excellent anti-ulcer activity but greatly lowered toxicity.

Abstract: A method is disclosed for preventing the recurrence of duodenal ulcer associated with Campylobacter pylori (Helicobacter pylori) infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound, a first antibiotic selected from the group consisting of tetracycline and penicillins, and a second antibiotic which is metronidazole.

Abstract: The present invention relates to a 2-aminoethanesulfonic acid zinc complex represented by the following formula: ##STR1## (wherein M is an alkali metal atom), to a process for producing the said complex from 2-aminoethanesulfonic acid and to use of the said complex as an anti-hepatitis agent, liver function improving agent and anti-ulcer agent. The said complex exhibits not only improved physiological activities such as anti-hepatitis activity, suppressory activity against liver-function disorder and anti-ulcer activity but also protective and restorative activity for the digestive tract.

Abstract: An improved immunogenic composition against human gastrin 17 comprising the peptide pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Ser-Ser-Pro-Pro-Pro-Pro-Cys (SEQ ID NO.: 1) coupled to an immunogenic carrier and pharmaceutical compositions containing the same.

Abstract: The present invention relates to a method for enhancing white blood cell functioning and metabolism on a mucosal surface of a mammal. The present invention also relates to a method for treating or preventing a condition in a mammal caused by the presence of a disease-causing agent on a mucosal surface or a cutaneous surface wherein the disease-causing agent can be diminished by the actions of the white blood cells. The present invention yet also relates to a method for healing a wound of a mucosal or cutaneous surface. The present invention also relates to compositions for use in such methods.

Abstract: The use is described of both (i) ranitidine bismuth citrate and (ii) a non-steroidal anti-inflammatory drug in treating or preventing inflammatory conditions and for analgesia. Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.

Abstract: The invention relates to a pharmaceutical composition, which is useful in the treatment of gastrointestinal disorders, especially gastric ulcer, duodenal ulcer and gastritis. The pharmaceutical composition is composed of Rhizoma coptidis extract, Radix scutellariae extract, and Radix astragali extract. Processes for producing these components are provided.

Abstract: Free-flowing granular compositions principally for use in treatment of gastric disorders comprise (A) titanium dioxide having a particle size within the range from 10 nanometers to 60 nanometers and a specific BET (nitrogen) surface area of at least 30 m.sup.2 /g in combination with (B) an organopolysiloxane antifoam agent (for example a mixture of from 90 to 99 percent by weight of a polydiorganosiloxane and from 1 to 10 percent by weight of a finely-divided silica having a surface area to weight ratio of at least 50 m.sup.2 /g), (B) being present in a proportion of from 30 to 70 percent by weight calculated on the combined weight of (A) and (B). The compositions may contain from 40 to 60 percent of (B) based on the combined weight of (A) and (B). They may also contain an antacid or other medicament, glycerol, an effervescent agent and/or a disintegrant component.

Abstract: A method of improving the nutritional status and reversing the characteristic diarrhea and inflammatory condition in a mammalian creature having ulcerative colitis or inflammation of the colon which contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: A cell proliferation matrix consisting of an aqueous gel of hyaluronic acid or a pharmaceutically acceptable salt thereof which is free from production-related animal DNA and RNA and which is in a dissolved state, is disclosed. Further, the use of hyaluronic acid or a pharmaceutically acceptable salt thereof for the preparation of a cell proliferation matrix according to the invention, for the treatment of at least one of bone fractures, Ulcus Varicosum Cruris, and ulcera caused by Diabetes Mellitus and other diseases (e.g. Decubitus) with impaired arterial blood flow, is described. Also, a method of treating at least one of bone fractures, Ulcus Varicosum Cruris, and ulcera caused by Diabetes Mellitus and other diseases with impaired arterial blood flow is disclosed.

Abstract: A method of treating a mammal for the presence or the activity of H. pylori in the gastrointestinal tract is disclosed. The method encompasses orally administering to said mammal a sufficient amount of a scavenging, reacting or inactivating compound to remove bicarbonate ions, ammonium ions or urea which are present in combination with the microorganisms which colonize and infect the gastric mucosa. Such microorganisms have been implicated in gastritis, gastric ulcer disease and as a risk factor in gastric carcinoma.Also, the invention encompasses a method, utilizing similar compounds, for the treatment or prevention of dermatitis such as diaper rash wherein these compounds are preapplied to the skin or used to treat the diaper prior to use.Also included are compositions which are used for the methods described above.

Abstract: The present invention relates to a preparation, particularly a topical preparation, for the therapy of wounds or hemorrhoids, which contains, as an active ingredient, at least one of prostaglandin I.sub.2, prostaglandin E.sub.1 and derivatives of these, particularly beraprost, a derivative of prostaglandin I.sub.2, or a salt thereof, and a method of the therapy of wounds or hemorrhoids, which comprises administering the above active ingredient.

Abstract: This invention describes pharmaceutical compositions and methods of treating ulcerating diseases of the gastrointestinal tract in mammals with an acid-resistant fibroblast growth factor compositions. Also described is the use of acid-resistant fibroblast growth factor compositions in the treatment of various other fibroblast growth factor-responsive conditions.

Abstract: The invention relates to the use of preparations of the plant Curcuma longa or other curcumin-containing plants, curcumin or curcumin derivatives for the prophylaxis and/or treatment of conditions associated with excessive formation of leucotrienes and/or prostaglandins and to the use of preparations of the plant Curcuma longa or other curcumin-containing plants, curcumin or curcumin derivatives for the production of medicaments for the prophylaxis and/or treatment of conditions associated with excessive formation of leucotrienes and/or prostaglandins.

Abstract: Method of promoting healing of a wound by administering turmeric to a patient afflicted with the wound.

Abstract: The subject invention relates to methods for preventing or treating damage to the mucosal lining of the gastrointestinal tract of a human or lower animal by administering a safe and effective amount of a compound having the structure: ##STR1## wherein X and Y are each independently selected from O and S; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, hydroxy, halo, unsubstituted or monosubstituted straight or branched C.sub.1 -C.sub.4 alkanyl, and unsubstituted or substituted straight or branched C.sub.1 -C.sub.4 alkanoxy; and each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is hydrogen or, if one or more of R.sup.1, R.sup.2 and R.sup.3 is other than hydrogen, each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is selected from hydrogen, halo, trifluoromethyl, and unsubstituted straight or branched C.sub.1 -C.sub.4 alkanyl.

Abstract: The invention disclosed relates to treating aphthae by applying dimeticone to the afflicted oral mucosa.

Abstract: Described are methods for ameliorating symptoms associated with inflammatory bowel disease such as ulcerative colitis and Crohn's disease (regional enteritis) with four specific quinoline leukotriene synthesis inhibitors.

Abstract: The present invention relates to the surprising and unexpected discovery that a simple organic acid, lactic acid or its pharmaceutically compatible salts, may be used in a therapy for treating aphthous ulcers, including canker sores in humans.The therapeutic method according to the present invention comprises exposing tissue suffering from an outbreak of aphthous ulcers to an effective amount of lactic acid.

Abstract: A trialkylamine derivative represented by the formula (1) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents lower alkyl;R.sup.3, R.sup.4 and R.sup.5 may be the same or different from one another and each represents hydrogen, lower alkyl, lower alkoxy, lower alkoxycarbonyl or halogen;R.sup.6 and R.sup.7 may be the same or different from each other and each represents hydrogen or lower alkyl;R.sup.8 represents hydrogen, lower alkyl, lower alkoxy or halogen;X represents oxygen, sulfur, --CH.dbd.N-- or --CH.dbd.CH--;Y represents oxygen, sulfur, methylene, N--R.sup.11 (wherein R.sup.11 represents lower alkyl), SO or SO.sub.2 ;Z represents --OCO(CH.sub.2).sub.p .about. or --OCH.sub.2 (CH.sub.2).sub.p .about. (wherein p represents a number of 0 to 4 and symbol .about.

Abstract: Disclosed herein is purified isolated angiogenic factor, isolated from Live Yeast Cell Derivitive. Also disclosed herein are methods to treat mammals suffering from wounds or burns comprising administering the angiogenic factor and pharmaceutical formulations for use in the methods.

Abstract: The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.

Abstract: A method is provided for protecting against and/or treating ulcerative gastrointestinal conditions, including anti-inflammatory drug-induced gastrointestinal ulcers, using a thromboxane A.sub.2 receptor antagonist. In addition, a combination is provided which includes a thromboxane A.sub.2 receptor antagonist and an anti-inflammatory agent which combination may be used to treat inflammatory conditions, such as arthritis, while inhibiting formation of and/or treating gastrointestinal ulcers.

Abstract: Acidic polysaccharide esters containing carboxylic groups are useful for protecting against and curing ulcers of the gastro-enteric system. These esters include choline esters with acidic polysaccharide selected from the group consisting of hyaluronic acid, alginic acid, gellan, oxidized cellulose, oxidized chitin, carboxy-hydrocarbyl-cellulose, carboxy-hydrocarbyl-starch and carboxy-hydrocarbyl-chitin, wherein the term hydrocarbyl means the residue of a hydrocarbon selected from the group consisting of by alkyl, aralkyl and cycloalkyl.

Abstract: Antacid powders, tablets etc. of prolonged gastric residence time have an internal phase of a solid antacid and excipient surrounded by a solid external phase containing a hydrophobic substance e.g. an ester of glycerol with palmitic or stearic acid, a hydroxylated polyalkene and a non-ionic emulsifier.

Abstract: The invention provides compounds of the general formula (I) ##STR1## or a physiologically acceptable salt or solvate thereof, wherein Q represents a 1- or 2-naphthalenyl group.The compounds have a stimulant action at .beta..sub.2 -adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

Abstract: Compounds of the formulas ##STR1## wherein R.sup.1 is H and R.sup.2 is alkyl (3-8C) or wherein R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.n -- wherein n=3-5;R.sup.3 is H or alkyl (1-4C);R.sup.4 is a substituted or unsubstituted fused or conjugated bicycloaryl methylene;X is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); orX is an amino acid residue or amide thereof; orX is the residue of a cyclic amine or heterocyclic amineare useful for treating or preventing ulceration of tissue, especially cornea.

Abstract: Ulcerative conditions of the gastro-intestinal tract, e.g., antiinflammatory-drug-induced ulcers, are treated or prevented by the administration of a potassium channel activator. Methods and combination products are also disclosed for the treatment of inflammatory conditions without causing ulceration of the gastrointestinal tract.

Abstract: Medical materials for use in treating maladies in living beings, such as ulcers and other conditions of the digestive tract. In one form, a container is provided for a medication which container also contains an adhesive material which is operatively released from the container or exposed at the surface thereof upon biodegradation or dissolution of a protective coating or wall portion of the container under the effects of fluid in the digestive tract in which the container is exposed, such as by swallowing, to permit such adhesive to temporarily bond and retain the container at a select location in the digestive tract so that it may slowly release its contents thereafter to a select portion of the digestive tract. In another form, a multitude of microcapsules, each containing a small quantity of medication, is mixed with an adhesive material, such as a sucralfate other material which may be swallowed as a tablet or dissolved in a liquid such as water.

Abstract: Compositions and methods for protecting the luminal lining against gastric acid challenge are disclosed. The compositions provide effective anti-ulcer preparations which include phosphorylated alcohol. Phosphorylated alcohols comprise the active anti-ulcerogenic ingredient of the described therapeutic formulations. The preparation of unique linear and cyclic polyphosphorylated alcohols and methods of using same to protect the stomach luminal lining against acid challenge are also disclosed. Inositol hexaphosphate and mannitol hexaphosphate are demonstrated to provide therapeutic value in the treatment and prevention of gastro-erosive disease precipitated by exposure of biological tissues to highly acidic substances, for example, the gastric digestive acids. While inositol hexaphosphate alone at subthreshold concentrations provides a small gastro-protective activity, a combination of inositol hexaphosphate (at subthreshold concentrations) with polyvalent cations, such as Au.sup.+3 or Bi.sup.

Abstract: Pharmaceutical composition and process for administering NSAIDs with a combination of beta-adrenergic agonist and certain H.sub.1 -and H.sub.2 -receptor blockers which protect against injury to the gastrointestinal tract. Said composition being terbutaline, diphenhydramine and ranitidine.

Abstract: The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein is purified isolated angiogenic factor, isolated from Live Yeast Cell Derivative. Also disclosed herein are methods to treat mammals suffering from wounds or burns comprising administering the angiogenic factor and pharmaceutical formulations for use in the methods.

Abstract: The present invention relates to an anti-ulcer agent comprising a compound represented by the following general formula I as the effective ingredient, and a novel chalcone derivative included in the compound represented by this general formula I: ##STR1## wherein X and Y independently stand for a hydrogen atom or together form a single bond, R.sub.1 stands for a hydroxyl group, an acetoxy group, a carboxymethoxy group or a methoxycarbonylmethoxy group, R.sub.2 stands for a hydrogen atom, an isoprenyl group, isopentyl group or a propyl group, R.sub.3 stands for a hydroxyl group or a methoxy group, R.sub.4 stands for a hydrogen atom, a hydroxyl group or a methoxy group, R.sub.5 stands for a hydrogen atom, a hydroxyl group, a methoxy group or an isopentyl group, R.sub.6 stands for a hydroxyl group, a methoxy group or a carboxymethoxy group, and R.sub.7 stands for a hydrogen atom or a methoxy group.

Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.

Abstract: An injectable solution of a compound useful as an anti-ulcer agent of the formula; ##STR1## wherein R.sup.1 represents hydrogen, methoxy or trifluoromethyl group; R.sup.2 and R.sup.3, being the same as or different from each other, represent hydrogen or methyl group; and R.sup.4 represents a fluorinated C.sub.2 to C.sub.5 lower alkyl group, is provided by dissolving the compound in at least one of ethanol, propylene glycol and polyethylene glycol; or by dissolving the freeze-dried material of an alkaline aqueous solution of the compound in a mixture of an acidic substance and at least one of the above solvents.

Abstract: A method is disclosed for preventing recurrence of duodenal ulcer associated with Campylobacter pylori infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound; a first antibiotic selected from the group consisting of tetracycline and penicillins and second antibiotic which is metronidazole.

Abstract: The invention provides a pharmaceutical granule comprising cimetidine and 2-20% (w/w) relative to the cimetidine of a co-polymer of dimethylaminoethylmethacrylate and neutral methacrylic acid esters. Compositions of this invention have good palatability and dissolution characteristics.

Abstract: The present invention is related to the protection of moist stratified squamous epithelia against damage from exposure to noxious luminal agents. Protection of moist stratified squamous epithelia against these noxious luminal agents is afforded by chemical compounds having one of the following reactive groups in their molecule: X--SO.sub.3.sup.-, where X represents oxygen or carbon, and XO.sub.4.sup.= or X.sub.2 O.sub.7.sup.=, where X represents an element from group VIb or sulfur of group VIa of the periodic table. Compounds that provide protection against injury to moist stratified squamous epithelia that illustrate the protective characteristic of these reactive species are the sulfonates, the sulfate esters and the tetrahedral-shaped divalent oxy-anions of the transition metals in group VIb or of sulfur.

Abstract: This invention describes pharmaceutical compositions and methods of treating ulcerating diseases of the gastrointestinal tract in mammals with an acid-resistant fibroblast growth factor compositions. Also described is the use of acid-resistant fibroblast growth factor compositions in the treatment of various other fibroblast growth factor-responsive conditions.

Abstract: Complexes of sucralfate with alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin or 2-hydroxypropyl beta cyclodextrin are disclosed. Also disclosed are a process for producing complexes and compositions and a method for reducing gastric injury, employing the complexes.

Abstract: A topical emollient for the treatment of circulation induced lesions comprises a source of glucose and insulin. The topical emollient is utilized in a process wherein the emollient is applied to the affected surface for nourishment thereof and promotion of healing. The emollient also enhances the therapeutic benefits of other medicinal drugs which may be topically applied in conjunction with the insulin and glucose mixture.

Abstract: Disclosed are methods employing compositions composed of unique mixtures of phospholipids and neutral lipids to treat the luminal lining of the gastrointestinal tract in the prevention or treatment of ulcerogenic processes such as peptic ulcer disease and inflammatory bowel disease. Compositions including mixtures of saturated or unsaturated phospholipids, together with saturated or unsaturated triglycerides and/or sterols, are shown to provide a surprising ulcer protective efficacy in experimental models. Further enhancement of activity is found upon the addition of a polyvalent cation or antioxidant to the various lipid mixtures.The present invention also discloses unique methods employing mixtures of phospholipids and neutral lipids for surfactant replacement therapy in the treatment of the various forms of respiratory distress syndrome. These compositions are shown to greatly enhance the surfactant replacement efficiency of surface-active lipids.

Abstract: The present invention provides a polymer-combined drug having directional characteristics to digestive organs, wherein it comprises a medicine combined with a polymer which has an alkyleneoxy group as a repeating unit. The polymer-combined drug is produced by reacting a polyoxyalkylene glycol having one or more terminal functional groups and a medicine, if necessary in a solvent, and if necessary in the presence of a catalyst. It is able to administer the drug orally or by intravenous injection so as to maintain the concentration in blood stably for a long time, and to absorb or take in digestive organs such as the stomach and intestines directly.

Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.